Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)

C Seidel; J Busch; S Weikert; S Steffens; C Bokemeyer; V Grünwald

doi:10.1038/bjc.2013.662

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)

Standard

Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). / Seidel, C; Busch, J; Weikert, S; Steffens, S; Bokemeyer, C; Grünwald, V.

In: BRIT J CANCER, Vol. 109, No. 12, 10.12.2013, p. 2998-3004.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Seidel, C, Busch, J, Weikert, S, Steffens, S, Bokemeyer, C & Grünwald, V 2013, 'Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)', BRIT J CANCER, vol. 109, no. 12, pp. 2998-3004. https://doi.org/10.1038/bjc.2013.662

APA

Seidel, C., Busch, J., Weikert, S., Steffens, S., Bokemeyer, C., & Grünwald, V. (2013). Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). BRIT J CANCER, 109(12), 2998-3004. https://doi.org/10.1038/bjc.2013.662

Vancouver

Seidel C, Busch J, Weikert S, Steffens S, Bokemeyer C, Grünwald V. Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC). BRIT J CANCER. 2013 Dec 10;109(12):2998-3004. https://doi.org/10.1038/bjc.2013.662

Bibtex

@article{de0912cf1c5947728061611acf07e789,

title = "Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)",

abstract = "BACKGROUND: The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship.METHODS: A hundred patients were stratified into five subgroups according to their change of tumour size with first treatment evaluation: -100% to -60%; -59% to -30% and -29% to 0% TS or gain of tumour size from 1% to 19% and ≤20% or occurrence of new lesions (i.e., progressive disease).RESULTS: The median PFS and OS were 10.4 months and 28.2 months, respectively. The median OS stratified according to the subgroups as described above was 77.4, 33.5, 26.9, 30.0 and 14.3 months, respectively. Multivariate analysis revealed early TS as a prognostic marker (P=0.021; HR 1.624).CONCLUSION: The extent of TS defines a small proportion of patients with an excellent prognosis. Larger studies are warranted to define the relationship of long-term survivorship and extent of TS with targeted therapies.",

keywords = "Angiogenesis Inhibitors, Antineoplastic Agents, Carcinoma, Renal Cell, Disease-Free Survival, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Molecular Targeted Therapy, Neoplasm Metastasis, Prognosis, Protein Kinase Inhibitors, Survival Analysis, Treatment Outcome, Vascular Endothelial Growth Factor A",

author = "C Seidel and J Busch and S Weikert and S Steffens and C Bokemeyer and V Gr{\"u}nwald",

year = "2013",

month = dec,

day = "10",

doi = "10.1038/bjc.2013.662",

language = "English",

volume = "109",

pages = "2998--3004",

journal = "BRIT J CANCER",

issn = "0007-0920",

publisher = "NATURE PUBLISHING GROUP",

number = "12",

}

RIS

TY - JOUR

T1 - Tumour shrinkage measured with first treatment evaluation under VEGF-targeted therapy as prognostic marker in metastatic renal cell carcinoma (mRCC)

AU - Seidel, C

AU - Busch, J

AU - Weikert, S

AU - Steffens, S

AU - Bokemeyer, C

AU - Grünwald, V

PY - 2013/12/10

Y1 - 2013/12/10

N2 - BACKGROUND: The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship.METHODS: A hundred patients were stratified into five subgroups according to their change of tumour size with first treatment evaluation: -100% to -60%; -59% to -30% and -29% to 0% TS or gain of tumour size from 1% to 19% and ≤20% or occurrence of new lesions (i.e., progressive disease).RESULTS: The median PFS and OS were 10.4 months and 28.2 months, respectively. The median OS stratified according to the subgroups as described above was 77.4, 33.5, 26.9, 30.0 and 14.3 months, respectively. Multivariate analysis revealed early TS as a prognostic marker (P=0.021; HR 1.624).CONCLUSION: The extent of TS defines a small proportion of patients with an excellent prognosis. Larger studies are warranted to define the relationship of long-term survivorship and extent of TS with targeted therapies.

AB - BACKGROUND: The aim of our analysis is to further characterise the prognostic relevance of early tumour shrinkage (TS) during VEGF-targeted therapy in mRCC, in order to explore whether this could define a group of patients with long-term survivorship.METHODS: A hundred patients were stratified into five subgroups according to their change of tumour size with first treatment evaluation: -100% to -60%; -59% to -30% and -29% to 0% TS or gain of tumour size from 1% to 19% and ≤20% or occurrence of new lesions (i.e., progressive disease).RESULTS: The median PFS and OS were 10.4 months and 28.2 months, respectively. The median OS stratified according to the subgroups as described above was 77.4, 33.5, 26.9, 30.0 and 14.3 months, respectively. Multivariate analysis revealed early TS as a prognostic marker (P=0.021; HR 1.624).CONCLUSION: The extent of TS defines a small proportion of patients with an excellent prognosis. Larger studies are warranted to define the relationship of long-term survivorship and extent of TS with targeted therapies.

KW - Angiogenesis Inhibitors

KW - Antineoplastic Agents

KW - Carcinoma, Renal Cell

KW - Disease-Free Survival

KW - Female

KW - Humans

KW - Kidney Neoplasms

KW - Male

KW - Middle Aged

KW - Molecular Targeted Therapy

KW - Neoplasm Metastasis

KW - Prognosis

KW - Protein Kinase Inhibitors

KW - Survival Analysis

KW - Treatment Outcome

KW - Vascular Endothelial Growth Factor A

U2 - 10.1038/bjc.2013.662

DO - 10.1038/bjc.2013.662

M3 - SCORING: Journal article

C2 - 24169357

VL - 109

SP - 2998

EP - 3004

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 12

ER -